The Neuropsychopharmacology and Toxicology of 3,4-methylenedioxy-N-ethyl-amphetamine (MDEA). (Q30341737)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15179441%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

review article

1 reference

title

The Neuropsychopharmacology and Toxicology of 3,4-methylenedioxy-N-ethyl-amphetamine (MDEA) (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15179441%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

1

Roland W Freudenmann

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15179441%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

2

Manfred Spitzer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15179441%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

publication date

1 January 2004

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15179441%20AND%20SRC:MED&resulttype=core&format=json

CNS Neuroscience & Therapeutics

29 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15179441%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

volume

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15179441%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15179441%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

page(s)

89-116

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15179441%20AND%20SRC:MED&resulttype=core&format=json

Determination of phenylisothiocyanate derivatives of amphetamine and its analogues in biological fluids by HPLC-APCI-MS or DAD.

29 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2004.TB00007.X

Ecstacy: a review of MDMA and MDA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2004.TB00007.X

Designer drugs: past history and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2004.TB00007.X

Psychological effects of MDE in normal subjects. Are entactogens a new class of psychoactive agents?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2004.TB00007.X

Possible interaction between an MAOI and "ecstasy"

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2004.TB00007.X

Application of the Syva EMIT and Abbott TDx amphetamine immunoassays to the detection of 3,4-methylene-dioxymethamphetamine (MDMA) and 3,4-methylene-dioxyethamphetamine (MDEA) in urine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2004.TB00007.X

Evaluation of Roche Abuscreen ONLINE amphetamine immunoassay for screening of new amphetamine analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2004.TB00007.X

MDMA (ecstasy) inhibition of MAO type A and type B: comparisons with fenfluramine and fluoxetine (Prozac).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2004.TB00007.X

Multiplex assay of amphetamine, methamphetamine, and ecstasy drug using CEDIA technology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2004.TB00007.X

Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2004.TB00007.X

Ecstasy and neurodegeneration. No evidence of neurotoxicity exists

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2004.TB00007.X

Effect of serotonin depletion by p-chlorophenylalanine upon discriminative behaviours

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2004.TB00007.X

The background and chemistry of MDMA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2004.TB00007.X

21 January 2018

The serotonin syndrome

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2004.TB00007.X

Rapid simultaneous determination of amphetamine, methamphetamine, 3,4-methylenedioxyamphetamine, 3,4-methylenedioxymethamphetamine, and 3,4-methylenedioxyethylamphetamine in urine by solid-phase extraction and GC-MS: a method optimized for high-volu

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2004.TB00007.X

An "accidental" acute psychosis with ecstasy use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2004.TB00007.X

Profiles of urine samples taken from Ecstasy users at Rave parties: analysis by immunoassays, HPLC, and GC-MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2004.TB00007.X

21 January 2018

Fatal MDMA intoxication

1 reference

12 December 2020

Fatal MDMA intoxication

1 reference

12 December 2020

3,4-Methylenedioxy analogues of amphetamine: defining the risks to humans.

1 reference

12 December 2020

Ecstasy (MDMA) dependence.

1 reference

12 December 2020

Psychopathological, neuroendocrine and autonomic effects of 3,4-methylenedioxyethylamphetamine (MDE), psilocybin and d-methamphetamine in healthy volunteers. Results of an experimental double-blind placebo-controlled study.

1 reference

12 December 2020

Neurometabolic effects of psilocybin, 3,4-methylenedioxyethylamphetamine (MDE) and d-methamphetamine in healthy volunteers. A double-blind, placebo-controlled PET study with [18F]FDG.

1 reference

12 December 2020

The acute effect in rats of 3,4-methylenedioxyethamphetamine (MDEA, "eve") on body temperature and long term degeneration of 5-HT neurones in brain: a comparison with MDMA ("ecstasy").

1 reference

12 December 2020

Molecular cloning, expression and characterization of a bovine serotonin transporter

1 reference

12 December 2020

Adam (MDMA) and Eve (MDEA) misuse: an immunohistochemical study on three fatal cases

1 reference

12 December 2020

Congenital anomalies after prenatal ecstasy exposure.

1 reference

12 December 2020

"Ecstasy"-induced changes of cerebral glucose metabolism and their correlation to acute psychopathology. An 18-FDG PET study.

1 reference

12 December 2020

Non-linear pharmacokinetics of MDMA ('ecstasy') in humans

1 reference

12 December 2020

Serotonergic deficits and impaired passive-avoidance learning in rats by MDEA: a comparison with MDMA.

1 reference

12 December 2020

Screening experiments of ecstasy street samples using near infrared spectroscopy

1 reference

12 December 2020

Amphetamine designer drugs - an overview and epidemiology

1 reference

12 December 2020

Toxicokinetics and analytical toxicology of amphetamine-derived designer drugs ('Ecstasy')

1 reference

12 December 2020

Toxicodynamics and long-term toxicity of the recreational drug, 3, 4-methylenedioxymethamphetamine (MDMA, 'Ecstasy').

1 reference

12 December 2020

Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") are attenuated by the serotonin uptake inhibitor citalopram

1 reference

12 December 2020

Identification of the human cytochromes P450 involved in the oxidative metabolism of "Ecstasy"-related designer drugs

1 reference

12 December 2020

Impaired cognitive performance in drug free users of recreational ecstasy (MDMA)

1 reference

12 December 2020

MDMA stimulus generalization to the 5-HT(1A) serotonin agonist 8-hydroxy-2- (di-n-propylamino)tetralin

1 reference

12 December 2020

Composition profiling of seized ecstasy tablets by Raman spectroscopy

1 reference

12 December 2020

Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin

1 reference

12 December 2020

Pharmacology of MDMA in Humans

1 reference

12 December 2020

Ecstasy (MDMA): a review of its possible persistent psychological effects

1 reference

12 December 2020

Determination of the designer drugs 3, 4-methylenedioxymethamphetamine, 3,4-methylenedioxyethylamphetamine, and 3,4-methylenedioxyamphetamine with HPLC and fluorescence detection in whole blood, serum, vitreous humor, and urine.

1 reference

12 December 2020

Intravenous self-injection of four novel phenethylamines in baboons

1 reference

12 December 2020

Stereospecific analysis of ecstasy-like N-ethyl-3,4-methylenedioxyamphetamine and its metabolites in humans

1 reference

12 December 2020

Dextromethorphan and ecstasy pills

1 reference

12 December 2020

The use of drugs within the techno party scene in European metropolitan cities

1 reference

12 December 2020

Designer drugs in Jutland

1 reference

12 December 2020

Behavioural, hyperthermic and neurotoxic effects of 3,4-methylenedioxymethamphetamine analogues in the Wistar rat.

1 reference

12 December 2020

Drugs and the dance music scene: a survey of current drug use patterns among a sample of dance music enthusiasts in the UK.

1 reference

12 December 2020

Enantio-selective cognitive and brain activation effects of N-ethyl-3,4-methylenedioxyamphetamine in humans

1 reference

12 December 2020

Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substrates.

1 reference

12 December 2020

The pharmacology and toxicology of "ecstasy" (MDMA) and related drugs

1 reference

12 December 2020

Arginine vasopressin release in response to the administration of 3,4-methylenedioxymethamphetamine ("ecstasy"): is metabolism a contributory factor?

1 reference

12 December 2020

3,4-methylenedioxymethamphetamine (MDMA): a review

1 reference

12 December 2020

Assessing long-term effects of MDMA (Ecstasy).

1 reference

12 December 2020

The effect of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') and its metabolites on neurohypophysial hormone release from the isolated rat hypothalamus

1 reference

12 December 2020

Altered prolactin response to M-chlorophenylpiperazine in monkeys previously treated with 3,4-methylenedioxymethamphetamine (MDMA) or fenfluramine

1 reference

12 December 2020

Recreational Ecstasy/MDMA, the serotonin syndrome, and serotonergic neurotoxicity

1 reference

12 December 2020

How strong is the evidence that brain serotonin neurons are damaged in human users of ecstasy?

1 reference

12 December 2020

Drugs of abuse monitoring in blood for control of driving under the influence of drugs.

1 reference

12 December 2020

Toxicokinetics of amphetamines: metabolism and toxicokinetic data of designer drugs, amphetamine, methamphetamine, and their N-alkyl derivatives

1 reference

12 December 2020

Neuroendocrine abnormalities in recreational ecstasy (MDMA) users: is it ecstasy or cannabis?

1 reference

12 December 2020

Chronic neurotoxic damage in ecstasy (MDMA) users. Review of the current state of research

1 reference

12 December 2020

Acute hyponatraemia and 'ecstasy': insights from a quantitative and integrative analysis

1 reference

12 December 2020

Reduced (+/-)-3,4-methylenedioxymethamphetamine ("Ecstasy") metabolism with cytochrome P450 2D6 inhibitors and pharmacogenetic variants in vitro.

1 reference

12 December 2020

Long-term neuropsychiatric consequences of "ecstasy" (MDMA): a review

1 reference

12 December 2020

Therapeutic and adverse actions of serotonin transporter substrates

1 reference

12 December 2020

Subjective and hormonal effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans

1 reference

12 December 2020

Amphetamine derivative related deaths in northern Greece

1 reference

12 December 2020

Enantioselective metabolism of the designer drugs 3,4-methylenedioxymethamphetamine ('ecstasy') and 3,4-methylenedioxyethylamphetamine ('eve') isomers in rat brain and blood

1 reference

12 December 2020

Effects of amphetamine derivatives and cathinone on noradrenaline-evoked contractions of rat right ventricle

1 reference

12 December 2020

Interactions between recreational drugs and antiretroviral agents

1 reference

12 December 2020

Ecstasy counteracts catalepsy in rats, an anti-parkinsonian effect?

1 reference

12 December 2020

Rewarding effects of the optical isomers of 3,4-methylenedioxy-methylamphetamine ('Ecstasy') and 3,4-methylenedioxy-ethylamphetamine ('Eve') measured by conditioned place preference in rats

1 reference

12 December 2020

Retracted article on dopaminergic neurotoxicity of MDMA

1 reference

12 December 2020

Human psychopharmacology of Ecstasy (MDMA): a review of 15 years of empirical research

1 reference

12 December 2020

Functional consequences of perinatal exposure to 3,4-methylenedioxymethamphetamine in rat brain

1 reference

12 December 2020

The content of ecstasy tablets: implications for the study of their long-term effects.

1 reference

12 December 2020

Neuropharmacology and neurotoxicity of 3,4-methylenedioxymethamphetamine.

1 reference

12 December 2020

3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro

1 reference

12 December 2020

3,4-Methylenedioxymethamphetamine (MDMA) abuse may cause oxidative stress and potential free radical damage

1 reference

12 December 2020

The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy").

1 reference

12 December 2020

Toxicity and deaths from 3,4-methylenedioxymethamphetamine ("ecstasy")

1 reference

12 December 2020

The effects of MDMA and other methylenedioxy-substituted phenylalkylamines on the structure of rat locomotor activity

1 reference

12 December 2020

Neurotoxic amphetamine analogues: effects in monkeys and implications for humans

1 reference

12 December 2020

Sleep EEG effects of 3,4-methylenedioxyethamphetamine (MDE; "eve") in healthy volunteers

1 reference

12 December 2020

Phenylalkylamine stimulants, hallucinogens, and designer drugs

1 reference

12 December 2020

Possible serotonergic and dopaminergic mediation of the N-ethyl-3,4-methylenedioxyamphetamine discriminative stimulus

1 reference

12 December 2020

3,4-Methylenedioxyamphetamine (MDA) analogues exhibit differential effects on synaptosomal release of 3H-dopamine and 3H-5-hydroxytryptamine

1 reference

12 December 2020

Neurochemistry and neurotoxicity of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy").

1 reference

12 December 2020

Reversal of the acute effects of 3,4-methylenedioxymethamphetamine by 5-HT uptake inhibitors

1 reference

12 December 2020

Structure-activity relationships of MDMA and related compounds: a new class of psychoactive drugs?

1 reference

12 December 2020

(+)-N-methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine as a discriminative stimulus in studies of 3,4-methylenedioxy-methamphetamine-like behavioral activity

1 reference

12 December 2020

Effects of N-ethyl-3,4-methylenedioxyamphetamine (MDE) on central serotonergic and dopaminergic systems of the rat.

1 reference

12 December 2020

Direct central effects of acute methylenedioxymethamphetamine on serotonergic neurons

1 reference

12 December 2020

Characterization of acute N-ethyl-3,4-methylenedioxyamphetamine (MDE) action on the central serotonergic system

1 reference

12 December 2020

Hallucinogenic drug interactions at human brain 5-HT2 receptors: implications for treating LSD-induced hallucinogenesis

1 reference

12 December 2020

Pharmacologic profile of amphetamine derivatives at various brain recognition sites: selective effects on serotonergic systems

1 reference

12 December 2020

Behavioral effects of (+-) 3,4-methylenedioxyamphetamine (MDA) and (+-) 3,4-methylenedioxymethamphetamine (MDMA) in the pigeon: interactions with noradrenergic and serotonergic systems.

1 reference

12 December 2020

Stimulus effects of N-monoethyl-1-(3,4-methylenedioxyphenyl)-2-aminopropane (MDE) and N-hydroxy-1-(3,4-methylenedioxyphenyl)-2-aminopropane (N-OH MDA) in rats trained to discriminate MDMA from saline

1 reference

12 December 2020

Prepulse inhibition of the acoustic startle response is disrupted by N-ethyl-3,4-methylenedioxyamphetamine (MDEA) in the rat.

1 reference

12 December 2020

3,4-Methylenedioxymethamphetamine (MDMA): stereoselective interactions at brain 5-HT1 and 5-HT2 receptors

1 reference

12 December 2020

The effects of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) on monoaminergic systems in the rat brain

1 reference

12 December 2020

Can drugs be used to enhance the psychotherapeutic process?

1 reference

12 December 2020

Effects of the enantiomers of MDA, MDMA and related analogues on [3H]serotonin and [3H]dopamine release from superfused rat brain slices

1 reference

12 December 2020

'Eve' and 'Ecstasy'. A report of five deaths associated with the use of MDEA and MDMA

1 reference

12 December 2020

A comparison of the neurotoxic potential of methylenedioxyamphetamine (MDA) and its N-methylated and N-ethylated derivatives

1 reference

12 December 2020

A case of MAO inhibitor/MDMA interaction: agony after ecstasy

1 reference

12 December 2020

Acute administration of methylenedioxymethamphetamine: comparison with the neurochemical effects of its N-desmethyl and N-ethyl analogs

1 reference

12 December 2020

3,4-Methylenedioxyethylamphetamine (MDE), a novel analogue of MDMA, produces long-lasting depletion of serotonin in the rat brain

1 reference

12 December 2020

MDMA as a discriminative stimulus: isomeric comparisons

1 reference

12 December 2020

Behavioral effects of N-ethyl-3,4-methylenedioxyamphetamine (MDE; "EVE").

1 reference

12 December 2020

Stimulus properties of 1-(3,4-methylenedioxyphenyl)-2-aminopropane (MDA) analogs

1 reference

12 December 2020

Drug discrimination studies with MDMA and amphetamine

1 reference

12 December 2020

Pharmacologic profile of MDMA (3,4-methylenedioxymethamphetamine) at various brain recognition sites

1 reference

12 December 2020

Comparison of three commercial amphetamine immunoassays for detection of methamphetamine, methylenedioxyamphetamine, methylenedioxymethamphetamine, and methylenedioxyethylamphetamine

1 reference

12 December 2020

Differences between rats and mice in MDMA (methylenedioxymethylamphetamine) neurotoxicity.

1 reference

12 December 2020

Ring-substituted amphetamine interactions with neurotransmitter receptor binding sites in human cortex

1 reference

12 December 2020

Subjective effects of 3,4-methylenedioxymethamphetamine in recreational users.

1 reference

12 December 2020

Serotonergic-dopaminergic mediation of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy").

1 reference

12 December 2020

In vivo and in vitro metabolism of 3,4-(methylenedioxy)methamphetamine in the rat: identification of metabolites using an ion trap detector

1 reference

12 December 2020

Hallucinogenic amphetamine selectively destroys brain serotonin nerve terminals

1 reference

12 December 2020

Structure–Activity Relationships of One-Ring Psychotomimetics

1 reference

12 December 2020

Centrally active N-substituted analogs of 3,4-methylenedioxyphenylisopropylamine (3,4-methylenedioxyamphetamine)

1 reference

12 December 2020

Effects of certain hallucinogenic amphetamine analogues on the release of [3H]serotonin from rat brain synaptosomes

1 reference

12 December 2020

Reorganization of ascending 5-HT axon projections in animals previously exposed to the recreational drug (+/-)3,4-methylenedioxymethamphetamine (MDMA, "ecstasy")

1 reference

12 December 2020

High-pressure liquid chromatography/electrochemical detection method for monitoring MDA and MDMA in whole blood and other biological tissues

1 reference

12 December 2020

A fatal overdose with 3,4-methylenedioxyamphetamine derivatives

1 reference

12 December 2020

The demethylenation of methylenedioxymethamphetamine ("ecstasy") by debrisoquine hydroxylase (CYP2D6)

1 reference

12 December 2020

Immunocytochemical evidence for serotonergic neurotoxicity of N-ethyl-methylenedioxyamphetamine (MDE).

1 reference

12 December 2020

A case of toxic psychosis induced by 'eve' (3,4-methylene-dioxyethylam-phetamine)

1 reference

12 December 2020

Hyperthermia associated with 3,4-methylenedioxyethamphetamine ('Eve').

1 reference

12 December 2020

Amphetamine and other weak bases act to promote reverse transport of dopamine in ventral midbrain neurons.

1 reference

12 December 2020

Neuroendocrine and cardiovascular effects of MDE in healthy volunteers

1 reference

12 December 2020

Analysis of the enantiomers of 3,4-methylenedioxy-N-ethylamphetamine (MDE, “Eve”) and its metabolite 3,4-methylenedioxyamphetamine (MDA) in rat brain

1 reference

12 December 2020

Release of serotonin induced by 3,4-methylenedioxymethamphetamine (MDMA) and other substituted amphetamines in cultured fetal raphe neurons: further evidence for calcium-independent mechanisms of release

1 reference

12 December 2020

Two very different fatal cases associated with the use of methylenedioxyethylamphetamine (MDEA): Eve as deadly as Adam

1 reference

12 December 2020

Pathology of deaths associated with "ecstasy" and "eve" misuse

1 reference

12 December 2020

"ADAM' or "EVE'?--a toxicological conundrum

1 reference

12 December 2020

Fatal poisoning by MDMA (ecstasy) and MDEA: a case report

1 reference

12 December 2020

[Acute fatal poisoning caused by methylenedioxyamphetamine]

1 reference

12 December 2020

On the metabolism and the toxicological analysis of methylenedioxyphenylalkylamine designer drugs by gas chromatography-mass spectrometry

1 reference

12 December 2020

Metabolism of racemic 3,4-methylenedioxyethylamphetamine in humans. Isolation, identification, quantification, and synthesis of urinary metabolites

1 reference

12 December 2020

Toxicological detection of the designer drug 3,4-methylenedioxyethylamphetamine (MDE, "Eve") and its metabolites in urine by gas chromatography-mass spectrometry and fluorescence polarization immunoassay.

1 reference

12 December 2020

[Entactogenic drugs "ecstasy" (MDMA), "eve" (MDE) and other ring-substituted methamphetamine derivatives. A new class of substances among illegal designer drugs?].

1 reference

12 December 2020

High-performance thin-layer chromatographic determination of N-ethyl-3,4-methylenedioxyamphetamine and its major metabolites in urine and comparison with high-performance liquid chromatography

1 reference

12 December 2020

Amphetamine derivative related deaths.

1 reference

12 December 2020

[Epidemiology of designer drug use in Spain]

1 reference

12 December 2020

Ecstasy--the status in French-speaking Switzerland. Composition of seized drugs, analysis of biological specimens and short review of its pharmacological action and toxicity

1 reference

12 December 2020

A study of the neurotoxic effect of MDMA ('ecstasy') on 5-HT neurones in the brains of mothers and neonates following administration of the drug during pregnancy

1 reference

12 December 2020

1 reference

12 December 2020

Interactions of amphetamine analogs with human liver CYP2D6

1 reference

12 December 2020

Carrier-dependent and Ca(2+)-dependent 5-HT and dopamine release induced by (+)-amphetamine, 3,4-methylendioxymethamphetamine, p-chloroamphetamine and (+)-fenfluramine.

1 reference

12 December 2020

Mood and cognitive effects of +/-3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy'): week-end 'high' followed by mid-week low.

1 reference

12 December 2020

Causes and consequences of the loss of serotonergic presynapses elicited by the consumption of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") and its congeners

1 reference

12 December 2020

Mechanisms of amphetamine action revealed in mice lacking the dopamine transporter

1 reference

12 December 2020

Musical preference as an indicator of adolescent drug use.

1 reference

12 December 2020

Optical isomer analysis of 3,4-methylene-dioxyamphetamine analogues and their stereoselective disposition in rats

1 reference

12 December 2020

'Candyflipping': synergistic discriminative effect of LSD and MDMA.

1 reference

12 December 2020

Lethal monointoxication by overdosage of MDEA.

1 reference

12 December 2020

Intentional overdose and death with 3,4-methylenedioxyethamphetamine (MDEA; "Eve"): case report

1 reference

12 December 2020

Determination of drugs of abuse in blood.

1 reference

12 December 2020

Characterization of the translocation of protein kinase C (PKC) by 3,4-methylenedioxymethamphetamine (MDMA/ecstasy) in synaptosomes: evidence for a presynaptic localization involving the serotonin transporter (SERT).

1 reference

12 December 2020

Ecstasy (MDMA) effects upon mood and cognition: before, during and after a Saturday night dance

1 reference

12 December 2020

Fatal interaction between ritonavir and MDMA

1 reference

12 December 2020

Quantitation of N-ethyl-3,4-methylenedioxyamphetamine and its major metabolites in human plasma by high-performance liquid chromatography and fluorescence detection

1 reference

12 December 2020

1 reference

12 December 2020

Recreational drugs. Current trends in the 90s.

1 reference

12 December 2020

10.1111/J.1527-3458.2004.TB00007.X

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15179441%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15179441%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

PubMed publication ID

15179441

1 reference